AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

Collaboration Across CNS, Immunology, Oncology

 
• By Mandy Jackson
  
AbbVie and ADARx plan to combine their capabilities to develop siRNA medicines (Shutterstock)

More from Deals

More from Scrip